title: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.
abstract: OBJECTIVE
  To evaluate the efficacy of diethylpropion on a long-term basis, with emphasis in cardiovascular and psychiatric safety aspects.
  
  
  METHODS
  Randomized, double-blind, placebo-controlled trial.
  
  
  METHODS
  Following a 2-week screening period, 69 obese healthy adults received a hypocaloric diet and were randomized to diethylpropion 50 mg BID (n=37) or placebo (n=32) for 6 months. After this period, all participants received diethylpropion in an open-label extension for an additional 6 months. The primary outcome was percentage change in body weight. Electrocardiogram (ECG), echocardiography and clinical chemistry were performed at baseline and every 6 months. Psychiatric evaluation and application of Hamilton rating scales for depression and anxiety were also performed by experienced psychiatrists at baseline and every 3 months.
  
  
  RESULTS
  After 6 months, the diethylpropion group lost an average of 9.8% (s.d. 6.9%) of initial body weight vs 3.2% (3.7%) in the placebo group (P<0.0001). From baseline to month 12, the mean weight loss produced by diethylpropion was 10.6% (8.3%). Participants in the placebo group who were switched to diethylpropion after 6 months lost an average of 7.0% (7.7%) of initial body weight. The difference between groups at month 12 was not significant (P=0.07). No differences in blood pressure, pulse rate, ECG and psychiatric evaluation were observed. Dry mouth and insomnia were the most frequent adverse events.
  
  
  CONCLUSIONS
  Diethylpropion plus diet produced sustained and clinically significant weight loss over 1 year. It seems to be safe in relation to cardiovascular and psychiatric aspects in a well-selected population.
authors: Obesity and Metabolic Syndrome Group, Endocrinology and Metabolism Department, Hospital das Clínicas, University of São Paulo-Brazil, Rua Dr Enéas de Carvalho Aguiar 155, São Paulo, Brazil. ccercato@netpoint.com.br
authors: C
authors: C
authors: Cercato
authors: V A
authors: VA
authors: Roizenblatt
authors: C C
authors: CC
authors: Leança
authors: A
authors: A
authors: Segal
authors: A P
authors: AP
authors: Lopes Filho
authors: M C
authors: MC
authors: Mancini
authors: A
authors: A
authors: Halpern
mesh_terms: D000328:Adult; D001067:Appetite Depressants / Q000627:therapeutic use*; D001835:Body Weight; D004038:Diet, Reducing; D004053:Diethylpropion / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos / Q000627:therapeutic use; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects* / Q000502:physiology
chemical_list: D001067:Appetite Depressants; D010919:Placebos; D004053:Diethylpropion